CL2020002622A1 - Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos - Google Patents

Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Info

Publication number
CL2020002622A1
CL2020002622A1 CL2020002622A CL2020002622A CL2020002622A1 CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1 CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1
Authority
CL
Chile
Prior art keywords
antibodies
graft rejection
prevention
therapies
kits
Prior art date
Application number
CL2020002622A
Other languages
English (en)
Inventor
Pascal Espie
James Rush
Boerje Haraldsson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002622A1 publication Critical patent/CL2020002622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos, regímenes de tratamiento, usos, kits y terapias para prevenir el rechazo de injertos en el trasplante de órganos sólidos, mediante el empleo de anticuerpos anti-CD40.
CL2020002622A 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos CL2020002622A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
EP18208332 2018-11-26

Publications (1)

Publication Number Publication Date
CL2020002622A1 true CL2020002622A1 (es) 2021-04-16

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002622A CL2020002622A1 (es) 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Country Status (13)

Country Link
US (1) US11780927B2 (es)
EP (1) EP3774913A1 (es)
JP (2) JP6861301B2 (es)
KR (1) KR20200143718A (es)
CN (1) CN111971307A (es)
AU (1) AU2019252858A1 (es)
BR (1) BR112020020277A2 (es)
CA (1) CA3094600A1 (es)
CL (1) CL2020002622A1 (es)
IL (1) IL277828A (es)
MX (1) MX2020010722A (es)
TW (1) TW201943731A (es)
WO (1) WO2019198019A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
US20230203176A1 (en) * 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
SI3178851T1 (sl) 2010-03-31 2020-09-30 Boehringer Inhelheim International Gmbh Anti-CD40 protitelesa
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40

Also Published As

Publication number Publication date
CN111971307A (zh) 2020-11-20
JP2020519634A (ja) 2020-07-02
KR20200143718A (ko) 2020-12-24
MX2020010722A (es) 2020-11-06
CA3094600A1 (en) 2019-10-17
WO2019198019A1 (en) 2019-10-17
JP6861301B2 (ja) 2021-04-21
IL277828A (en) 2020-11-30
AU2019252858A1 (en) 2020-10-08
EP3774913A1 (en) 2021-02-17
JP2021113190A (ja) 2021-08-05
TW201943731A (zh) 2019-11-16
US20210079107A1 (en) 2021-03-18
BR112020020277A2 (pt) 2021-01-19
US11780927B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PH12020552229A1 (en) Il-11ra antibodies
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
MX2020003605A (es) Manipulación del metabolismo de triptamina.
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al